Pharma and European Biotech – ¨4DJFODFUP.BSLFU§ … · Pharma and European Biotech –...
Transcript of Pharma and European Biotech – ¨4DJFODFUP.BSLFU§ … · Pharma and European Biotech –...
17th and 18th OctOber 2012 | dresden | Germany
business development conference
Special Partners:
European Partner:
Pharma and European Biotech –Alliances for Mutual Success
Platinum Sponsor:
Silver Sponsors:
Conference Supporters:
Gold Sponsors:
Media Partners:
European Association of Pharma Biotechnology EAPB
Second Announcement
»Science to Market«A Discussion and Partnering Conference for Experts from Academia, Biotechnology and Pharmaceutical Industry
October 6 – 7, 2009 | Convention Center, Hannover | Germany
Organised by the European Association of Pharma Biotechnology – EAPB in cooperation with BIOTECHNICA
CMYK
Blue: 100/15/0/35Orange: 0/75/90/0
Vereniging Biotechnologische Farmaceutische Industrie
Tite
lfoto
: ww
w.p
ixel
quel
le.d
e
Company Presentations: Wednesday, 17th October 2012
11.45 – 12.45 · PePperPrint
· roche
· Biotype Diagnostic
· JaDO technologies / Smartmab
14.00 – 15.00 · GanymeD Pharmaceuticals
· inflarx
· mSD
· t-cell europe
16.45 – 17.45 · biocrea
· epomedics
· Lipopharma
· Carpegen
Company Presentations: thursday, 18th October 2012
10.00 – 11.00 · Urotiss
· nOxxOn Pharma
· apceth
· medigene
DAY ONE: Wednesday, 17th October 2012
Moderation: Martin Pfister, High-tech Gründerfonds
10.30 – 11.00 registration / Breakfast
11.00 – 11.15 Opening remarks Peter Heinrich, BiO Deutschland
11.15 – 11.45 Keynote: The secrets of value creation in the life sciences
Klaus Hieke, PriceSpective
11.45 – 12.45 Company Presentations
12.45 – 13.45 Lunch
13.45 – 14.00 Dirk Hilbert, Dresden’s First mayor and Deputy mayor for economic affairs
14.00 – 15.00 Company Presentations
15.00 – 16.15 Session I:
Neurodegenerative and psychiatric disorders – coping with societal changes
moderator: Bernadett Simon, DZne
Patrick Benz, Janssen-Cilag Philip Iredale, Pfizer Timo Veromaa, Biotie Dieter Ziegler, abbott
16.15 – 16.45 Coffee Break
16.45 – 17.45 Company Presentations
17.45 – 19.15 Session II:
New models and a new spirit for financing innovation
moderator: Wolfgang Weitnauer
Titta Rosvall-Puplett, eBe Paul-Georg Germann, takeda Wolfgang Klein, amD therapy Olivier Litzka, rothschild investment Partners Karlheinz Schmelig, Creathor Venture management
20.00 – 22.30 Dinner
DAY TWO: thursday, 18th October 2012
09.00 – 09.30 registration / Breakfast
09.30 – 10.00 Keynote: Shaping the future of the biopharma business
Susan Herbert, merck Serono
10.00 – 11.00 Company Presentations
11.00 – 11.30 Coffee Break
11.30 – 13.00 Session III:
New antibiotics or alternatives to treat multi drugs resistances?
moderator: Frank Brunkhorst, Sepnet
Rodger Novak, Sanofi Helga Rübsamen-Schaeff, aiCuris
13.00 – 14.00 Lunch
14.00 – 15.30 Session IV:
New trends and models for mitigating risks
Keynote: Mitigating risks by co-development in personalized medicine
Stephen Little, Qiagen
moderator: Christine Lemke, Bayer
Paola Casarosa, Boehringer ingelheim Christoph Hüls, merck Serono Stephen Little, Qiagen Patricia Ruiz-Noppinger,
metanomics Health
15.30 – 15.45 Closing remarks
15.45 Departure